Neuroimmunomodulation: impairment of humoral immune responsiveness by 6-hydroxydopamine treatment.
Previous studies from this laboratory and others show that perturbations of the central nervous system modulate immune function. In addition, reports from several investigators indicate that depletion of the neurotransmitter norepinephrine (NE) in peripheral nerves by injecting the neurotoxin 6-hydroxydopamine (6-OHDA), can enhance or suppress the antibody response. However, immunocompetence following brain depletion of catecholamines has not been investigated. In this study, we investigated the effects of injecting 6-OHDA into the cisterna magna of male CBA/J mice, and determined the effects of this treatment on both the IgM and IgG antibody responses to sheep red blood cells (SRBC). Both responses are suppressed compared to saline-injected control or normal animals. Animals treated with 6-OHDA have decreased levels of NE in the midbrain, pons-medulla and hypothalamus, while dopamine levels did not change in these brain regions but was decreased in the striatum. The percentage of splenic T cells and B cells was not affected by 6-OHDA treatment. Although there is a marked increase in plasma corticosterone levels in 6-OHDA-treated mice, saline-injected control animals have equivalent increases in plasma corticosterone without concomitant impairment of the immune response. Thus, the decline in immune responsiveness following 6-OHDA treatment does not result from corticosterone-induced immunosuppression. Analysis of the kinetics of the primary IgG response following 6-OHDA treatment indicates that the magnitude, but not the kinetics, of the response decreases. Experiments to determine the effects of 6-OHDA on the afferent and efferent phrases of the response demonstrate that it is effective only when administered prior to immunization, and thus must inhibit early events involved in the initiation of the response. Additional experiments show that mice can be immunized 2 weeks following brain catecholamines depletion and still exhibit a decreased antibody response. However, the response returns to normal levels if immunization is delayed 4 weeks after injection. Further experiments demonstrated that 6-OHDA treatment has no effect on the secondary antibody response, but does inhibit the development of immunological memory. Collectively, these results indicate that 6-OHDA treatment has a profound inhibitory effect on the induction of the primary antibody response and immunological memory development, but is without effect on the secondary antibody response. The data further substantiate the existence of a link between the brain and the immune response.
Cross
R J
RJ
Jackson
J C
JC
Brooks
W H
WH
Sparks
D L
DL
Markesbery
W R
WR
Roszman
T L
TL
D000818:Animals; D000917:Antibody Formation / Q000187:drug effects; D001402:B-Lymphocytes; D001921:Brain / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism; D002946:Cisterna Magna; D003345:Corticosterone / Q000097:blood; D004298:Dopamine / Q000378:metabolism; D006462:Hemolytic Plaque Technique; D006892:Hydroxydopamines / Q000494:pharmacology*; D007074:Immunoglobulin G / Q000096:biosynthesis*; D007075:Immunoglobulin M / Q000096:biosynthesis*; D007156:Immunologic Memory / Q000187:drug effects; D008297:Male; D051379:Mice; D008808:Mice, Inbred CBA; D009638:Norepinephrine / Q000378:metabolism; D016627:Oxidopamine; D013154:Spleen / Q000166:cytology; D013601:T-Lymphocytes; D013997:Time Factors
D006892:Hydroxydopamines; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D016627:Oxidopamine; D004298:Dopamine; D003345:Corticosterone; D009638:Norepinephrine